Search Results
You are looking at 1 - 2 of 2 items for :
- Author: Min-Ji Kim x
- Thyroid cancer - clinical x
Search for other papers by Hyunju Park in
Google Scholar
PubMed
Search for other papers by Jung Heo in
Google Scholar
PubMed
Search for other papers by Hyun Jin Ryu in
Google Scholar
PubMed
Search for other papers by Min-Ji Kim in
Google Scholar
PubMed
Search for other papers by Young Lyun Oh in
Google Scholar
PubMed
Search for other papers by Tae Hyuk Kim in
Google Scholar
PubMed
Search for other papers by Sun Wook Kim in
Google Scholar
PubMed
Search for other papers by Jae Hoon Chung in
Google Scholar
PubMed
Objective
Previous reports suggest that a high body mass index (BMI) increases the risk of thyroid carcinoma. However, it remains unclear whether a high BMI is associated with the risk of the BRAFV600E mutation. We aimed to assess whether a high BMI is associated with an increased risk of the BRAFV600E mutation.
Design and Methods
We screened 6558 PTC patients who had undergone BRAFV600E mutation testing between January 2009 and December 2017. After exclusion, 6438 PTC patients were enrolled. We used logistic regression, and restricted cubic spline plots of the adjusted odds ratios (ORs) were illustrated to model the relationship between BMI and the BRAFV600E mutation.
Results
Of the 6438 patients, 5102 (79.2%) had the BRAFV600E mutation, and 4954 (76.9%) were female. The median BMI was 23.8 (21.6–26.2) kg/m2. The primary tumor size was ≤1 cm in 4226 patients (65.6%) and >1 cm in 2212 patients (34.4%). The BRAFV600E mutation was significantly associated with high BMI only in patients with a primary tumor size >1 cm (OR: 1.034; 95% CI: 1.003–1.065; P = 0.029), whereas no clear association was found in patients with a primary tumor size ≤1 cm (OR: 1.007; 95% CI: 0.984–1.030; P = 0.570). Gender was not a significant factor in either group.
Conclusions
Our study found that a higher BMI was positively associated with the BRAFV600E mutation in patients with a primary tumor size >1 cm. These results suggest that the association between BMI and the BRAFV600E mutation status differs depending on primary tumor size.
Significance Statement
Obesity has been suggested as a potential risk factor for thyroid carcinoma. The aim of this study was to assess the association between BMI and the BRAFV600E mutation. In this study, the BRAFV600E mutation was significantly associated with a high BMI only in a primary tumor size >1 cm (OR: 1.034; P = 0.029). No clear association was found in patients with a primary tumor size ≤1 cm (OR: 1.007; P = 0.570). The association between BMI and the BRAFV600E mutation status differs depending on the primary tumor size.
Search for other papers by Sang-Hyeon Ju in
Google Scholar
PubMed
Search for other papers by Yong Bae Ji in
Google Scholar
PubMed
Search for other papers by Minchul Song in
Google Scholar
PubMed
Search for other papers by Joung Youl Lim in
Google Scholar
PubMed
Search for other papers by Da Beom Heo in
Google Scholar
PubMed
Search for other papers by Min-Gyu Kim in
Google Scholar
PubMed
Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea
Search for other papers by Jae Won Chang in
Google Scholar
PubMed
Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University Sejong Hospital, Sejong, Republic of Korea
Search for other papers by Ho-Ryun Won in
Google Scholar
PubMed
Search for other papers by Yea Eun Kang in
Google Scholar
PubMed
Search for other papers by Eu Jeong Ku in
Google Scholar
PubMed
Search for other papers by Mijin Kim in
Google Scholar
PubMed
Search for other papers by Eun Kyung Lee in
Google Scholar
PubMed
Search for other papers by June Young Choi in
Google Scholar
PubMed
Search for other papers by Hyeong Won Yu in
Google Scholar
PubMed
Search for other papers by Young Joo Park in
Google Scholar
PubMed
Search for other papers by Jun-Ho Choe in
Google Scholar
PubMed
Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea
Search for other papers by Bon Seok Koo in
Google Scholar
PubMed
Search for other papers by the MASTER study group † in
Google Scholar
PubMed
Objective
Active surveillance (AS) is generally accepted as an alternative to immediate surgery for papillary thyroid carcinoma (PTC) measuring ≤1.0 cm (cT1a) without risk factors. This study investigated the clinicopathologic characteristics of PTCs measuring ≤2.0 cm without cervical lymph node metastasis (cT1N0) by tumor size group to assess the feasibility of AS for PTCs between 1.0 cm and 1.5 cm (cT1b≤1.5).
Design
This study enrolled clinically T1N0 patients with preoperative ultrasonography information (n= 935) from a cohort of 1259 patients who underwent lobectomy and were finally diagnosed with PTC from June 2020 to March 2022.
Results
The cT1b≤1.5 group (n = 171; 18.3 %) exhibited more lymphatic invasion and occult central lymph node (LN) metastasis with a higher metastatic LN ratio than the cT1a group (n = 719; 76.9 %). However, among patients aged 55 years or older, there were no significant differences in occult central LN metastasis and metastatic LN ratio between the cT1a, cT1b≤1.5, and cT1b>1.5 groups. Multivariate regression analyses revealed that occult central LN metastasis was associated with age, sex, tumor size, extrathyroidal extension, and lymphatic invasion in patients under 55, while in those aged 55 or older, it was associated only with age and lymphatic invasion.
Conclusion
For PTC patients aged 55 years or older with cT1b≤1.5, AS could be a viable option due to the absence of a significant relationship between tumor size and occult central LN.
